Final analysis of a phase II trial of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma without transplant.
作者:
主题词
人类(Humans);多发性骨髓瘤(Multiple Myeloma);地塞米松(Dexamethasone);女(雌)性(Female);男(雄)性(Male);中年人(Middle Aged);老年人(Aged);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);寡肽类(Oligopeptides);抗体, 单克隆(Antibodies, Monoclonal);成年人(Adult);肿瘤, 残余(Neoplasm, Residual);治疗结果(Treatment Outcome)
DOI
10.1038/s41408-024-01045-3
PMID
38811560
发布时间
2024-11-07
- 浏览0
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文